Kluwer Patent Blog

Napp v. Ratiopharm, Court of Appeal Civil Division (Court of Appeal Civil Division), 01 April 2009

Robert Burrows (Bristows) · Wednesday, April 1st, 2009 · Landmark European Patent Cases

The Court of Appeal has overturned the High Court's finding of non-infringement, holding Napp's divisional patents, relating to controlled release formulations of a painkiller called oxycodone, to be valid and infringed by Ratiopharm's and Sandoz's 'Cimex' product. The Court of Appeal's finding of infringement contrasts with decisions in Germany where the German designation of the patents were found to be not infringed.

The full summary of this case has been published on Kluwer IP Law.

To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe here.

Kluwer IP Law


The **2022 Future Ready Lawyer survey** showed that 79% of lawyers think that the importance of legal technology will increase for next year. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?

Learn how **Kluwer IP Law** can support you.

79% of the lawyers think that the importance of legal technology will increase for next year.

Drive change with Kluwer IP Law.

The master resource for Intellectual Property rights and registration.



The Wolters Kluwer Future Ready Lawyer

Leading change



This entry was posted on Wednesday, April 1st, 2009 at 8:39 am and is filed under Biologics, Case Law, Extent of Protection, Scope of protection, United Kingdom

You can follow any responses to this entry through the Comments (RSS) feed. Both comments and pings are currently closed.